期刊
ENDOCRINE-RELATED CANCER
卷 22, 期 3, 页码 353-367出版社
BIOSCIENTIFICA LTD
DOI: 10.1530/ERC-15-0038
关键词
gigantism; X chromosome; pituitary adenoma; pediatric; X-LAG syndrome; GPR101; FIPA; duplication
资金
- US Department of Health and Human Services-National Institutes of Health-National Institute of Child Health and Human Development [Z01-HD008920]
- US Department of Health and Human Services-National Institutes of Health-National Human Genome Research Institute [U54HG006542]
- Fonds D'Investissement de Recherche Scientifique, CHU de Liege
- Jabbs Foundation
- National Institute of Neurological Disorders and Stroke (NINDS) [R01 NS058529]
X-linked acrogigantism (X-LAG) is a new syndrome of pituitary gigantism, caused by microduplications on chromosome Xq26.3, encompassing the gene GPR101, which is highly upregulated in pituitary tumors. We conducted this study to explore the clinical, radiological, and hormonal phenotype and responses to therapy in patients with X-LAG syndrome. The study included 18 patients (13 sporadic) with X-LAG and microduplication of chromosome Xq26.3. All sporadic cases had unique duplications and the inheritance pattern in two families was dominant, with all Xq26.3 duplication carriers being affected. Patients began to grow rapidly as early as 2-3 months of age (median 12 months). At diagnosis (median delay 27 months), patients had a median height and weight standard deviation scores (SDS) of > +3.9 SDS. Apart from the increased overall body size, the children had acromegalic symptoms including acral enlargement and facial coarsening. More than a third of cases had increased appetite. Patients had marked hypersecretion of GH/IGF1 and usually prolactin, due to a pituitary macroadenoma or hyperplasia. Primary neurosurgical control was achieved with extensive anterior pituitary resection, but postoperative hypopituitarism was frequent. Control with somatostatin analogs was not readily achieved despite moderate to high levels of expression of somatostatin receptor subtype-2 in tumor tissue. Postoperative use of adjuvant pegvisomant resulted in control of IGF1 in all five cases where it was employed. X-LAG is a new infant-onset gigantism syndrome that has a severe clinical phenotype leading to challenging disease management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据